Nestle S.A. / Allergan plc

Exocrine Pancreatic Insufficiency (Pancreatic Enzyme Replacement Therapy)

800K US cases/yr · $1.5B U.S. PERT market 2020 · ~$1,500-$2,500 Average WAC per patient/month for branded PERT

Disease Overview

Exocrine pancreatic insufficiency (EPI) is a malabsorption syndrome caused by inadequate pancreatic enzyme secretion (lipase, amylase, protease) leading to fat maldigestion, steatorrhea, weight loss, and fat-soluble vitamin deficiencies. Approximately 800,000-1,000,000 U.S. patients have clinically significant EPI driven primarily by chronic pancreatitis (40-50%), pancreatic resection or duct obstruction (15-20%), cystic fibrosis (CF, ~30,000 U.S. patients almost universally affected), pancreatic cancer, and post-Whipple surgical states. Pediatric CF historically anchored the EPI pancreatic enzyme replacement therapy (PERT) market, but adult chronic pancreatitis and post-acute-pancreatitis populations now drive incremental volume. Standard of care is lifelong PERT dosed by lipase units per gram of dietary fat (typically 25,000-80,000 lipase units per meal). The U.S. PERT market consists of porcine-derived enteric-coated formulations across five branded products: Creon (AbbVie), Zenpep (Nestle/originally Allergan), Pancreaze (VIVUS), Pertzye (Chiesi), and Viokace (Nestle, the only non-enteric-coated PERT for use with PPI). Branded WAC ranges $1,200-$2,500 per month.

Competitive Landscape

The U.S. PERT competitive landscape is a five-product oligopoly built on porcine-derived pancrelipase, all FDA-approved between 2009-2012 following an FDA mandate requiring NDA submission for previously grandfathered enzyme products. Creon (pancrelipase, AbbVie) is the entrenched market leader with approximately 60-70% U.S. PERT volume share. Zenpep (pancrelipase, Nestle Health Science via the 2020 Allergan divestiture; originally Eurand/Aptalis/Forest/Actavis legacy) is the #2 brand. Pancreaze (pancrelipase, VIVUS) and Pertzye (pancrelipase, Chiesi) are smaller players. Viokace (pancrelipase, Nestle, non-enteric-coated, used with proton-pump inhibitor) addresses a niche subset where gastric acid neutralization is required. All five products share the same MOA (porcine pancrelipase enzyme replacement) and differentiate primarily on enteric coating microsphere size, capsule strength range, and managed-care contracting. There are no novel mechanisms in late-stage development. Recombinant non-porcine PERT alternatives (e.g. Anthera's liprotamase) failed Phase 3, leaving porcine pancrelipase as the entrenched standard. The Allergan divestiture transferred Zenpep/Viokace to Nestle Health Science to satisfy FTC concerns over PERT category overlap.